Summary
[JiuzhouPharmaceutical:Itisestimatedthattheannualnetprofitin2021willbeabout609millionyuantoabout685millionyuananincreaseof60%to80%year-on-year]Jiuzhou Pharmaceutical (SH 603456) released a performance forecast on the evening of January 18. The company expects 2021 The annual net profit attributable to shareholders of the listed company is about 609 million yuan to about 685 million yuan, which will increase by about 228 million yuan to about 304 million yuan compared with the same period of the previous year, a year-on-year increase of 60% to 80%. (Daily Economic News)
Jiuzhou Pharmaceutical(SH 603456, closing price: 51.38 yuan) Released on the evening of January 18performanceAnnouncement, the company expects to be attributable to listed companies in 2021shareholderofnet profitFrom about 609 million yuan to about 685 million yuan, compared with the same period of the previous year, it will increase by about 228 million yuan to about 304 million yuan, an increase of 60% to 80%. The main reason for the change in performance was the impact of the main business. This year’s performance growth is mainly due to the continuous growth of the company’s CDMO business. In 2021, based on years of industry leading advantages and platform effects, the company will continue to deepen the CDMO business, always adhere to customer demand-oriented, in-depth expansion of customer pipelines and product pipelines, and steadily improve the company’s R&D Ability and product delivery ability, further realize the improvement and increment of CDMO business, and realize the sustained and rapid development of the company’s CDMO business. The impact of non-operating profit and loss. The company’s non-recurring gains and losses are mainly due to the impact of government subsidies and forward foreign exchange settlement and sales. After deducting the impact of income tax, the amount of non-recurring gains and losses increased by about 2.3 million yuan over the same period of the previous year.
According to the 2020 annual report,Jiuzhou Pharmaceutical‘s main business isChemical materialsThe production and sales of medicines and intermediates accounted for 93.93% of the revenue.
Jiuzhou PharmaceuticalThe general manager and chairman of the board are Hua Lirong, female, 54 years old, with a master’s degree.
(Article source: Daily Economic News)
Article source: Daily Economic News
Responsible editor: 91
Original title: Pre-increment! Jiuzhou Pharmaceutical: It is estimated that the annual net profit in 2021 will be about 609 million yuan to about 685 million yuan, a year-on-year increase of 60% to 80%
Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.
report
Scan the QR code to follow
Oriental Fortune official website WeChat
.